1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Alzheimer%s Disease Therapeutics and Diagnostics: Global Markets



Use this report to:

Define AD and discuss disease-related events, etiology and epidemiology of AD.
Investigate the global and regional markets for the drugs and diagnostic technologies for the treatment of Alzheimer’s disease (AD).
Analyze market dynamics for the interpretation and forecasting of the sales of AD drugs and diagnostics.
Evaluate the developments in the global market for AD therapeutics and diagnostics.

Highlights

The global market for AD therapeutics and diagnostics by region should reach over $6.2 billion by 2020 from $4.4 billion in 2015, a compound annual growth rate (CAGR) of 7.1% from 2015 to 2020.
The North American market should reach over $2.9 billion by 2020 from 2.2 billion in 2015, at a CAGR of 5.3% from 2015 to 2020.
The Asia-Pacific market should reach over $2.6 billion by 2020 from $1.6 billion in 2015, at a CAGR of 10.7% from 2015 to 2020.

STUDY OBJECTIVES

The aim of this report is to investigate the global and regional markets for the drugs and diagnostic technologies used for the treatment and diagnostic evaluation of Alzheimer’s disease (AD).
This report defines AD and discusses the disease-related events, etiology and epidemiology of AD by providing information on prevalence and incidence rates, diagnostic tools and equipment, and by introducing important scientific and technological frameworks to better grasp the developments in the global market for AD therapeutics and diagnostics.

Products that are currently available for the diagnosis and treatment of AD are introduced and evaluated according to the report’s methodology. The report also highlights promising new drug candidates and diagnostic imaging agents.

Key drivers and restraints, as well as major opportunities versus threats for the future growth and direction of the individual and global markets, are identified and addressed.

The classification and comparison of distinct segments of AD drugs and diagnostic imaging products are provided in the report, and current and future developments are highlighted for each existing and novel market segment.
Current market dynamics and characteristics are analyzed for the interpretation and forecasting of the sales of AD drugs and diagnostics. Product revenues are broken down by regional and country markets. Sales figures are estimated for the global and regional markets for the period between 2015 and 2020.

REASONS FOR DOING THE STUDY

Alzheimer’s disease cannot be prevented, cured or slowed, and it is a rapidly growing and serious health problem, affecting more than 17 million worldwide. Therapies for AD provide temporary and modest improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease progression. The mmense size of the affected population and lack of appropriate and effective treatment offers a tremendous commercial opportunity.

The understanding of the underlying reasons and mechanisms involved in AD is very limited. Drug developers have been failing to demonstrate meaningful clinical benefits of treatment for a myriad of investigational compounds due to stringent regulations.

High drug attrition rates and long drug approval times have driven pharmaceutical companies and technology ventures closer to each for collaboration. Specifically, diagnostic technology companies are rigorously trying to bring about effective biomarker technologies to assist and enhance the drug development process for prospective drug candidates. Regulatory bodies are highly supportive of the use of diagnostic technologies in order to improve drug attrition rates.

Despite the recurring failures in the development of novel therapies for AD, the global markets are demanding new and more effective, disease attenuating treatments, with first-in-class approvals. This expectation and the increasing incidence of AD associated with the aging population are driving the market.


Table Of Contents

Alzheimer%s Disease Therapeutics and Diagnostics: Global Markets
CHAPTER 1 INTRODUCTION 2
STUDY OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
INTENDED AUDIENCE 3
SCOPE OF THE STUDY 3
INFORMATION SOURCES 3
METHODOLOGY 4
ANALYST'S CREDENTIALS 4
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH WEBSITE 4
DISCLAIMER 5
CHAPTER 2 SUMMARY 7
SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS) 11
SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY REGION, 2014-2020 ($ MILLIONS) 11
CHAPTER 3 OVERVIEW 13
ALZHEIMER'S DISEASE: DEFINITION AND MARKET STRUCTURE 13
FIGURE 1 CHANGE IN ALZHEIMER'S POPULATION AND COST OF CARE IN THE U.S.,
2015-2030 (MILLIONS/$ BILLIONS) 14
ALZHEIMER'S DISEASE PATHOPHYSIOLOGY 15
AD AND AMYLOID CASCADE 16
AD AND TAUOPATHY 18
AD AND NEUROTRANSMITTER SYSTEMS 18
ALZHEIMER'S DISEASE ETIOLOGY 19
GENETIC FACTORS 19
Early-Onset Familial AD 19
Late-Onset Sporadic AD 20
NON-GENETIC FACTORS 20
ALZHEIMER'S DISEASE EPIDEMIOLOGY 20
AGE OF ONSET 20
INCIDENCE, PREVALENCE AND MORTALITY 21
Incidence of AD 21
Prevalence of AD 21
TABLE 1 PREVALENCE RATES OF ALZHEIMER'S BY REGION, 2014 (%) 21
FIGURE 2 GLOBAL PREVALENCE RATES OF ALZHEIMER'S BY AGE GROUP AND
REGION (%) 21
TABLE 2 GLOBAL ALZHEIMER'S POPULATION BY AGE GROUP AND REGION, 2014
(MILLIONS) 22
FIGURE 3 GLOBAL ALZHEIMER'S POPULATION BY AGE GROUP AND REGION, 2014
(MILLIONS) 22
Mortality in AD 23
STAGES AND SEVERITY OF AD 23
Stage 1: Asymptomatic AD 23
Stage 2: Very mild AD 23
Stage 3: Mild AD 23
Stage 4: Moderate AD 24
Stage 5: Moderately severe AD 24
Stage 6: Severe decline 24
Stage 7: Very severe AD 24
COMORBIDITIES 25
TABLE 3 PHARMACOLOGICAL TREATMENT OF BPSD OF ALZHEIMER'S 26
DIAGNOSIS AND TREATMENT OF ALZHEIMER'S 26
DIAGNOSIS OF ALZHEIMER'S 26
Cognitive Status Testing 27
ADAS-Cog 28
Computerized Screening Tests 28
TABLE 4 COMPUTERIZED SCREENING TESTS USED IN DETECTING COGNITIVE
IMPAIRMENT 29
Genetic Testing 29
Brain Imaging 29
TABLE 5 BRAIN IMAGING TECHNOLOGIES AND APPLICATION IN THE ALZHEIMER'S
CONTEXT 30
Lumbar Puncture 30
PHARMACEUTICAL TREATMENT OF AD 30
CHAPTER 4 REGULATORY LANDSCAPE 33
U.S. FOOD AND DRUG ADMINISTRATION 33
TABLE 6 DIAGNOSTIC IMAGING TRACERS APPROVED BY THE FDA 35
EUROPEAN MEDICINES AGENCY 35
CHAPTER 5 GLOBAL MARKETS 38
INTRODUCTION 38
MARKET DYNAMICS 38
TOP PLAYERS IN THE GLOBAL MARKET FOR AD THERAPEUTICS 39
TABLE 7 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ALZHEIMER'S
THERAPEUTICS, 2020 (%) 40
FIGURE 4 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ALZHEIMER'S
THERAPEUTICS, 2020 (%) 40
GLOBAL MARKET FOR AD THERAPEUTICS AND DIAGNOSTICS 41
MARKET BY REGION 41
FIGURE 5 GLOBAL MARKET SHARES OF ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY REGION, 2015 (%) 41
TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY
REGION, THROUGH 2020 ($ MILLIONS) 43
FIGURE 6 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS
BY REGION, 2014-2020 ($ MILLIONS) 43
MARKET BY APPLICATION SEGMENT 43
TABLE 9 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY
APPLICATION, THROUGH 2020 ($ MILLIONS) 44
FIGURE 7 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS
BY APPLICATION, 2014-2020 ($ MILLIONS) 44
Global Market for AD Therapeutics 44
Global Market for AD Therapeutics by Region 45
TABLE 10 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY REGION,
THROUGH 2020 ($ MILLIONS) 46
FIGURE 8 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY REGION,
2014-2020 ($ MILLIONS) 46
Global Market for Branded/Generic AD Therapeutics 47
TABLE 11 GLOBAL MARKET FOR GENERIC/BRANDED ALZHEIMER'S THERAPEUTICS,
THROUGH 2020 ($ MILLIONS) 48
FIGURE 9 GLOBAL MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS,
2014-2020 ($ MILLIONS) 48
Global Market for AD Therapeutics by Mechanism of Action 49
TABLE 12 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF
ACTION, THROUGH 2020 ($ MILLIONS) 50
FIGURE 10 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF
ACTION, 2014-2020 ($ MILLIONS) 50
Global Market for AChEIs 51
TABLE 13 GLOBAL MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE
INHIBITORS, THROUGH 2020 ($ MILLIONS) 52
FIGURE 11 GLOBAL MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE
INHIBITORS, 2014-2020 ($ MILLIONS) 52
TABLE 14 GLOBAL MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY REGION,
THROUGH 2020 ($ MILLIONS) 53
FIGURE 12 GLOBAL MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY REGION,
2014-2020 ($ MILLIONS) 53
Global Market for NMDA Drugs 54
TABLE 15 GLOBAL MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH
2020 ($ MILLIONS) 54
FIGURE 13 GLOBAL MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 ($
MILLIONS) 54
TABLE 16 GLOBAL MARKET FOR NMDA DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 55
FIGURE 14 GLOBAL MARKET FOR NMDA DRUGS BY REGION, 2014-2020 ($
MILLIONS) 55
Global Market for Other AD Therapeutics 56
TABLE 17 GLOBAL MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY REGION,
THROUGH 2020 ($ MILLIONS) 57
FIGURE 15 GLOBAL MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY REGION,
2014-2020 ($ MILLIONS) 57
Global Market for AD Therapeutics by AD Stage 57
TABLE 18 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE,
THROUGH 2020 ($ MILLIONS) 59
FIGURE 16 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE,
2014-2020 ($ MILLIONS) 59
Global Market for AD Diagnostics 60
Global AD Diagnostics Market by Region 60
TABLE 19 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY REGION,
THROUGH 2020 ($ MILLIONS) 61
FIGURE 17 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY REGION,
2014-2020 ($ MILLIONS) 61
Global AD Diagnostics Market by Molecular Target 62
TABLE 20 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR
TARGET, THROUGH 2020 ($ MILLIONS) 63
FIGURE 18 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR
TARGET, 2014-2020 ($ MILLIONS) 63
CHAPTER 6 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS 65
NORTH AMERICAN MARKET 65
TABLE 21 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS) 65
FIGURE 19 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS) 65
NORTH AMERICAN MARKET FOR AD THERAPEUTICS BY COUNTRY 66
TABLE 22 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY
COUNTRY, THROUGH 2020 ($ MILLIONS) 66
FIGURE 20 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY
COUNTRY, 2014-2020 ($ MILLIONS) 67
NORTH AMERICAN MARKET FOR BRANDED/GENERIC AD THERAPEUTICS 67
TABLE 23 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S
THERAPEUTICS, THROUGH 2020 ($ MILLIONS) 68
FIGURE 21 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S
THERAPEUTICS, 2014-2020 ($ MILLIONS) 68
NORTH AMERICAN MARKET FOR AD THERAPEUTICS BY MECHANISM OF
ACTION 68
TABLE 24 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY
MECHANISM OF ACTION, THROUGH 2020 ($ MILLIONS) 69
FIGURE 22 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY
MECHANISM OF ACTION, 2014-2020 ($ MILLIONS) 69
North American Market for AChEIs 70
TABLE 25 NORTH AMERICAN MARKET FOR BRANDED/GENERIC
ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS) 70
FIGURE 23 NORTH AMERICAN MARKET FOR BRANDED/GENERIC
ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 ($ MILLIONS) 70
TABLE 26 NORTH AMERICAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS
BY COUNTRY, THROUGH 2020 ($ MILLIONS) 71
FIGURE 24 NORTH AMERICAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS
MARKET BY COUNTRY, 2014-2020 ($ MILLIONS) 71
North American Market for NMDA Drugs 72
TABLE 27 NORTH AMERICAN MARKET FOR BRANDED/GENERIC NMDA DRUGS,
THROUGH 2020 ($ MILLIONS) 72
FIGURE 25 NORTH AMERICAN MARKET FOR BRANDED/GENERIC NMDA DRUGS,
2014-2020 ($ MILLIONS) 73
TABLE 28 NORTH AMERICAN MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH
2020 ($ MILLIONS) 73
FIGURE 26 NORTH AMERICAN MARKET FOR NMDA DRUGS BY COUNTRY,
2014-2020 ($ MILLIONS) 73
North American Market for Other AD Therapeutics 74
TABLE 29 NORTH AMERICAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY
COUNTRY, THROUGH 2020 ($ MILLIONS) 75
FIGURE 27 NORTH AMERICAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS
BY COUNTRY, 2014-2020 ($ MILLIONS) 75
NORTH AMERICAN MARKET FOR AD THERAPEUTICS BY AD STAGE 75
TABLE 30 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY
DISEASE STAGE, THROUGH 2020 ($ MILLIONS) 76
FIGURE 28 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY
DISEASE STAGE 2014-2020 ($ MILLIONS) 76
NORTH AMERICAN MARKET FOR AD DIAGNOSTICS BY MOLECULAR TARGET 77
TABLE 31 NORTH AMERICAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY
MOLECULAR TARGET, THROUGH 2020 ($ MILLIONS) 78
FIGURE 29 NORTH AMERICAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY
MOLECULAR TARGET, 2014-2020 ($ MILLIONS) 78
CHAPTER 7 EUROPEAN MARKETS FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS 80
EUROPEAN MARKETS 80
TABLE 32 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS) 80
FIGURE 30 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS) 80
EUROPEAN MARKET FOR AD THERAPEUTICS BY COUNTRY 81
TABLE 33 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY,
THROUGH 2020 ($ MILLIONS) 82
FIGURE 31 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY,
2014-2020 ($ MILLIONS) 82
EUROPEAN MARKET FOR BRANDED/GENERIC AD THERAPEUTICS 82
TABLE 34 EUROPEAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S
THERAPEUTICS, THROUGH 2020 ($ MILLIONS) 83
FIGURE 32 EUROPEAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S
THERAPEUTICS, 2014-2020 ($ MILLIONS) 83
EUROPEAN MARKET FOR AD THERAPEUTICS BY MECHANISM OF ACTION 84
TABLE 35 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM
OF ACTION, THROUGH 2020 ($ MILLIONS) 86
FIGURE 33 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM
OF ACTION, 2014-2020 ($ MILLIONS) 86
European Market for AChEIs 86
TABLE 36 EUROPEAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE
INHIBITORS, THROUGH 2020 ($ MILLIONS) 87
FIGURE 34 EUROPEAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE
INHIBITORS, 2014-2020 ($ MILLIONS) 87
TABLE 37 EUROPEAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY
COUNTRY, THROUGH 2020 ($ MILLIONS) 88
FIGURE 35 EUROPEAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY
COUNTRY, 2014-2020 ($ MILLIONS) 88
European Market for NMDA Drugs 88
TABLE 38 EUROPEAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH
2020 ($ MILLIONS) 89
FIGURE 36 EUROPEAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020
($ MILLIONS) 89
TABLE 39 EUROPEAN MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 ($
MILLIONS) 90
FIGURE 37 EUROPEAN MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 ($
MILLIONS) 90
European Markets for Other AD Therapeutics 91
TABLE 40 EUROPEAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY
COUNTRY, THROUGH 2020 ($ MILLIONS) 91
FIGURE 38 EUROPEAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY
COUNTRY, THROUGH 2020 ($ MILLIONS) 91
EUROPEAN MARKET FOR AD THERAPEUTICS BY AD STAGE 92
TABLE 41 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE
STAGE, THROUGH 2020 ($ MILLIONS) 93
FIGURE 39 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE
STAGE, 2014-2020 ($ MILLIONS) 93
EUROPEAN MARKET FOR AD DIAGNOSTICS 93
TABLE 42 EUROPEAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR
TARGET, THROUGH 2020 ($ MILLIONS) 94
FIGURE 40 EUROPEAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR
TARGET, 2014-2020 ($ MILLIONS) 95
CHAPTER 8 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS 97
ASIA-PACIFIC MARKET 97
TABLE 43 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS) 97
FIGURE 41 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS) 97
ASIA-PACIFIC MARKET FOR AD THERAPEUTICS BY REGION 98
TABLE 44 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY,
THROUGH 2020 ($ MILLIONS) 99
FIGURE 42 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY,
THROUGH 2020 ($ MILLIONS) 99
ASIA-PACIFIC MARKET FOR BRANDED/GENERIC AD THERAPEUTICS 100
TABLE 45 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ALZHEIMER'S
THERAPEUTICS, THROUGH 2020 ($ MILLIONS) 100
FIGURE 43 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ALZHEIMER'S
THERAPEUTICS, 2014-2020 ($ MILLIONS) 100
ASIA-PACIFIC MARKET FOR AD THERAPEUTICS BY MECHANISM OF ACTION 101
TABLE 46 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM
OF ACTION, THROUGH 2020 ($ MILLIONS) 102
FIGURE 44 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY
MECHANISM OF ACTION, 2014-2020 ($ MILLIONS) 102
Asia-Pacific's Market for AChEIs 102
TABLE 47 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC
ACETYLCHOLIN-ESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS) 103
FIGURE 45 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC
ACETYLCHOLIN-ESTERASE INHIBITORS, 2014-2020 ($ MILLIONS) 103
TABLE 48 ASIA-PACIFIC MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY
COUNTRY, THROUGH 2020 ($ MILLIONS) 104
FIGURE 46 ASIA-PACIFIC MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY
COUNTRY, 2014-2020 ($ MILLIONS) 104
Asia-Pacific Market for NMDA Drugs 104
TABLE 49 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH
2020 ($ MILLIONS) 105
FIGURE 47 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC NMDA DRUGS,
2014-2020 ($ MILLIONS) 105
TABLE 50 ASIA-PACIFIC MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020
($ MILLIONS) 106
FIGURE 48 ASIA-PACIFIC MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 ($
MILLIONS) 106
ASIA-PACIFIC MARKET FOR AD THERAPEUTICS BY AD STAGE 106
TABLE 51 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE
STAGE, THROUGH 2020 ($ MILLIONS) 107
FIGURE 49 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE
STAGE, 2014-2020 ($ MILLIONS) 107
ASIA-PACIFIC MARKET FOR AD DIAGNOSTICS 108
TABLE 52 ASIA-PACIFIC MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR
TARGET, THROUGH 2020 ($ MILLIONS) 109
FIGURE 50 ASIA-PACIFIC MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR
TARGET, 2014-2020 ($ MILLIONS) 109
CHAPTER 9 PIPELINE ANALYSIS 111
AD PIPELINE LANDSCAPE 111
AD PIPELINE: CLINICAL STAGE 112
FIGURE 51 ALZHEIMER'S DRUGS IN THE PIPELINE BY DEVELOPMENT STAGE
(NUMBER OF DRUGS) 112
AD PIPELINE: TREATMENT FOCUS 112
FIGURE 52 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER
OF DRUGS) 113
AD PIPELINE BY DISEASE STAGE 114
FIGURE 53 LATE PHASE II/III ALZHEIMER'S DRUGS BY DISEASE STAGE (NUMBER OF
DRUGS) 114
AD PIPELINE: MECHANISM OF ACTION 115
FIGURE 54 GLOBAL CLINICAL TRIALS ON ALZHEIMER'S DRUG BY MECHANISM OF
ACTION (%) 116
TABLE 53 GLOBAL ALZHEIMER'S DRUGS IN THE PIPELINE BY MECHANISM OF
ACTION 116
MAJOR AB-BASED THERAPIES IN CLINICAL TRIALS 117
BIIB037/ADUCANUMAB 117
Mode of Action 117
Clinical Trial Snapshot 117
Phase I Trials 117
Phase III Trials 118
ENGAGE and EMERGE 118
Safety 118
Efficacy 118
Administration 118
SOLANEZUMAB/LY2062430 119
Mode of Action 119
Clinical Trial Snapshot 119
Phase I Trial 119
Phase II Trials 119
Phase III Trials 120
EXPEDITION 1 and 2 120
Safety 121
Efficacy 121
Administration 121
RG1450/GANTENERUMAB 121
Mode of Action 121
Clinical Trial Snapshot 121
Phase I Trials 121
Phase II/III Trials 122
Efficacy 122
Administration 122
RG7412/CRENEZUMAB 122
Mode of Action 123
Clinical Trial Snapshot 123
Phase I Trials 123
Phase II Trials 123
Safety 124
Efficacy 124
Administration 124
MK-8931/VERUBECESTAT 124
Mode of Action 124
Clinical Trial Snapshot 125
Phase I Trials 125
Phase II Trials 125
Phase III Trials 125
Safety 126
Efficacy 126
Administration 126
Benchmarking 126
CAD106 127
Mode of Action 127
Clinical Trial Snapshot 127
Phase I Trial 127
Phase II Trials 127
Phase III Trials 128
Safety 128
Efficacy 128
Administration 128
MAJOR TAU-BASED THERAPIES IN CLINICAL TRIALS 128
LMTX 128
Mode of Action 129
Clinical Trial Snapshot 129
Phase I and II Trials 129
Phase III Trials 129
Safety 130
Efficacy 130
Administration 130
CHAPTER 10 COMPANION DIAGNOSTICS 132
INTRODUCTION 132
FIGURE 55 FDA-APPROVED CDX TECHNOLOGIES BY INDICATED THERAPEUTIC
CLASS (%) 132
FIGURE 56 FDA-APPROVED CDX-DRUG PAIRS BY MOLECULAR TARGET 132
COMPANION IMAGING DIAGNOSTICS FOR AD 135
FIGURE 57 ONGOING AB AND TAU PET IMAGING CLINICAL TRIALS (%) 135
FIGURE 58 AB AND TAU PET IMAGING TRIALS BY CLINICAL TRIAL PHASE (NUMBER
OF TRIALS) 136
CIDX TECHNOLOGIES FOR AMYLOID VISUALIZATION 137
Market 137
TABLE 54 CIDX-DRUG PAIRS IN CLINICAL TRIALS 138
Pipeline 138
NAV-4694 138
Comparative Analysis of AB Tracer Technologies 139
Diagnostic Efficacy 139
Safety 139
Diagnostic Utility 139
CIDX TECHNOLOGIES FOR TAU-NFT VISUALIZATION 140
AV-1451 140
THK-5351 140
RO6958948 141
Comparative Analysis of Tau Tracers in Development 141
Diagnostic Efficacy 141
Safety 142
Diagnostic Utility 142
CIDX TECHNOLOGIES: AB VERSUS TAU IMAGING TECHNOLOGIES 142
CONCLUDING REMARKS 143
CHAPTER 11 COMPANY PROFILES 145
AB SCIENCE 145
ABBVIE INC. 145
AC IMMUNE SA 145
ALLERGAN PLC 146
AFFIRIS AG 146
AMARANTUS BIOSCIENCE HOLDINGS 146
ANAVEX LIFE SCIENCES 147
ASTRAZENECA 147
AVID RADIOPHARMACEUTICALS 148
AXON NEUROSCIENCE 148
AXOVANT SCIENCES 148
BIOGEN 149
BOEHRINGER INGELHEIM 149
DAIICHI SANKYO CO 149
DIAGENIC 150
EISAI 150
ELI LILLY 150
F. HOFFMANN LA ROCHE AG 151
GE HEALTHCARE 151
H. LUNDBECK A/S 151
JANSSEN PHARMACEUTICALS 152
MERCK and CO 152
NAVIDEA BIOPHARMACEUTICALS 152
NEUROTRAX CORP. 153
NOVARTIS PHARMA SERVICES AG 153
ONO PHARMACEUTICAL CO. 153
OTSUKA PHARMACEUTICALS 154
PFIZER INC 154
PIRAMAL IMAGING GMBH 154
TAURX THERAPEUTICS 155

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS) 11
TABLE 1 PREVALENCE RATES OF ALZHEIMER'S BY REGION, 2014 (%) 21
TABLE 2 GLOBAL ALZHEIMER'S POPULATION BY AGE GROUP AND REGION, 2014
(MILLIONS) 22
TABLE 3 PHARMACOLOGICAL TREATMENT OF BPSD OF ALZHEIMER'S 26
TABLE 4 COMPUTERIZED SCREENING TESTS USED IN DETECTING COGNITIVE
IMPAIRMENT 29
TABLE 5 BRAIN IMAGING TECHNOLOGIES AND APPLICATION IN THE ALZHEIMER'S
CONTEXT 30
TABLE 6 DIAGNOSTIC IMAGING TRACERS APPROVED BY THE FDA 35
TABLE 7 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ALZHEIMER'S
THERAPEUTICS, 2020 (%) 40
TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY
REGION, THROUGH 2020 ($ MILLIONS) 43
TABLE 9 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY
APPLICATION, THROUGH 2020 ($ MILLIONS) 44
TABLE 10 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY REGION, THROUGH
2020 ($ MILLIONS) 46
TABLE 11 GLOBAL MARKET FOR GENERIC/BRANDED ALZHEIMER'S THERAPEUTICS,
THROUGH 2020 ($ MILLIONS) 48
TABLE 12 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF
ACTION, THROUGH 2020 ($ MILLIONS) 50
TABLE 13 GLOBAL MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE
INHIBITORS, THROUGH 2020 ($ MILLIONS) 52
TABLE 14 GLOBAL MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY REGION,
THROUGH 2020 ($ MILLIONS) 53
TABLE 15 GLOBAL MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020
($ MILLIONS) 54
TABLE 16 GLOBAL MARKET FOR NMDA DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 55
TABLE 17 GLOBAL MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY REGION,
THROUGH 2020 ($ MILLIONS) 57
TABLE 18 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE,
THROUGH 2020 ($ MILLIONS) 59
TABLE 19 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY REGION, THROUGH
2020 ($ MILLIONS) 61
TABLE 20 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR
TARGET, THROUGH 2020 ($ MILLIONS) 63
TABLE 21 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS) 65
TABLE 22 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY
COUNTRY, THROUGH 2020 ($ MILLIONS) 66
TABLE 23 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S
THERAPEUTICS, THROUGH 2020 ($ MILLIONS) 68
TABLE 24 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY
MECHANISM OF ACTION, THROUGH 2020 ($ MILLIONS) 69
TABLE 25 NORTH AMERICAN MARKET FOR BRANDED/GENERIC
ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 ($ MILLIONS) 70
TABLE 26 NORTH AMERICAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY
COUNTRY, THROUGH 2020 ($ MILLIONS) 71
TABLE 27 NORTH AMERICAN MARKET FOR BRANDED/GENERIC NMDA DRUGS,
THROUGH 2020 ($ MILLIONS) 72
TABLE 28 NORTH AMERICAN MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH
2020 ($ MILLIONS) 73
TABLE 29 NORTH AMERICAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY
COUNTRY, THROUGH 2020 ($ MILLIONS) 75
TABLE 30 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE
STAGE, THROUGH 2020 ($ MILLIONS) 76
TABLE 31 NORTH AMERICAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY
MOLECULAR TARGET, THROUGH 2020 ($ MILLIONS) 78
TABLE 32 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS
BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS) 80
TABLE 33 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY,
THROUGH 2020 ($ MILLIONS) 82
TABLE 34 EUROPEAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS,
THROUGH 2020 ($ MILLIONS) 83
TABLE 35 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF
ACTION, THROUGH 2020 ($ MILLIONS) 86
TABLE 36 EUROPEAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE
INHIBITORS, THROUGH 2020 ($ MILLIONS) 87
TABLE 37 EUROPEAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY
COUNTRY, THROUGH 2020 ($ MILLIONS) 88
TABLE 38 EUROPEAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH
2020 ($ MILLIONS) 89
TABLE 39 EUROPEAN MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 ($
MILLIONS) 90
TABLE 40 EUROPEAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY
COUNTRY, THROUGH 2020 ($ MILLIONS) 91
TABLE 41 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE,
THROUGH 2020 ($ MILLIONS) 93
TABLE 42 EUROPEAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR
TARGET, THROUGH 2020 ($ MILLIONS) 94
TABLE 43 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 ($ MILLIONS) 97
TABLE 44 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY,
THROUGH 2020 ($ MILLIONS) 99
TABLE 45 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ALZHEIMER'S
THERAPEUTICS, THROUGH 2020 ($ MILLIONS) 100
TABLE 46 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM
OF ACTION, THROUGH 2020 ($ MILLIONS) 102
TABLE 47 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ACETYLCHOLIN-ESTERASE
INHIBITORS, THROUGH 2020 ($ MILLIONS) 103
TABLE 48 ASIA-PACIFIC MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY
COUNTRY, THROUGH 2020 ($ MILLIONS) 104
TABLE 49 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH
2020 ($ MILLIONS) 105
TABLE 50 ASIA-PACIFIC MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020
($ MILLIONS) 106
TABLE 51 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE
STAGE, THROUGH 2020 ($ MILLIONS) 107
TABLE 52 ASIA-PACIFIC MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR
TARGET, THROUGH 2020 ($ MILLIONS) 109
TABLE 53 GLOBAL ALZHEIMER'S DRUGS IN THE PIPELINE BY MECHANISM OF ACTION 116
TABLE 54 CIDX-DRUG PAIRS IN CLINICAL TRIALS 138

LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY REGION, 2014-2020 ($ MILLIONS) 11
FIGURE 1 CHANGE IN ALZHEIMER'S POPULATION AND COST OF CARE IN THE U.S.,
2015-2030 (MILLIONS/$ BILLIONS) 14
FIGURE 2 GLOBAL PREVALENCE RATES OF ALZHEIMER'S BY AGE GROUP AND
REGION (%) 21
FIGURE 3 GLOBAL ALZHEIMER'S POPULATION BY AGE GROUP AND REGION, 2014
(MILLIONS) 22
FIGURE 4 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ALZHEIMER'S
THERAPEUTICS, 2020 (%) 40
FIGURE 5 GLOBAL MARKET SHARES OF ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY REGION, 2015 (%) 41
FIGURE 6 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY
REGION, 2014-2020 ($ MILLIONS) 43
FIGURE 7 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY
APPLICATION, 2014-2020 ($ MILLIONS) 44
FIGURE 8 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY REGION,
2014-2020 ($ MILLIONS) 46
FIGURE 9 GLOBAL MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS,
2014-2020 ($ MILLIONS) 48
FIGURE 10 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF
ACTION, 2014-2020 ($ MILLIONS) 50
FIGURE 11 GLOBAL MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE
INHIBITORS, 2014-2020 ($ MILLIONS) 52
FIGURE 12 GLOBAL MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY REGION,
2014-2020 ($ MILLIONS) 53
FIGURE 13 GLOBAL MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 ($
MILLIONS) 54
FIGURE 14 GLOBAL MARKET FOR NMDA DRUGS BY REGION, 2014-2020 ($ MILLIONS) 55
FIGURE 15 GLOBAL MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY REGION,
2014-2020 ($ MILLIONS) 57
FIGURE 16 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE,
2014-2020 ($ MILLIONS) 59
FIGURE 17 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY REGION,
2014-2020 ($ MILLIONS) 61
FIGURE 18 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR
TARGET, 2014-2020 ($ MILLIONS) 63
FIGURE 19 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS) 65
FIGURE 20 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY
COUNTRY, 2014-2020 ($ MILLIONS) 67
FIGURE 21 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S
THERAPEUTICS, 2014-2020 ($ MILLIONS) 68
FIGURE 22 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY
MECHANISM OF ACTION, 2014-2020 ($ MILLIONS) 69
FIGURE 23 NORTH AMERICAN MARKET FOR BRANDED/GENERIC
ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 ($ MILLIONS) 70
FIGURE 24 NORTH AMERICAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS
MARKET BY COUNTRY, 2014-2020 ($ MILLIONS) 71
FIGURE 25 NORTH AMERICAN MARKET FOR BRANDED/GENERIC NMDA DRUGS,
2014-2020 ($ MILLIONS) 73
FIGURE 26 NORTH AMERICAN MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020
($ MILLIONS) 73
FIGURE 27 NORTH AMERICAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY
COUNTRY, 2014-2020 ($ MILLIONS) 75
FIGURE 28 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY
DISEASE STAGE 2014-2020 ($ MILLIONS) 76
FIGURE 29 NORTH AMERICAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY
MOLECULAR TARGET, 2014-2020 ($ MILLIONS) 78
FIGURE 30 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS) 80
FIGURE 31 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY,
2014-2020 ($ MILLIONS) 82
FIGURE 32 EUROPEAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S
THERAPEUTICS, 2014-2020 ($ MILLIONS) 83
FIGURE 33 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM
OF ACTION, 2014-2020 ($ MILLIONS) 86
FIGURE 34 EUROPEAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE
INHIBITORS, 2014-2020 ($ MILLIONS) 87
FIGURE 35 EUROPEAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY
COUNTRY, 2014-2020 ($ MILLIONS) 88
FIGURE 36 EUROPEAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020
($ MILLIONS) 89
FIGURE 37 EUROPEAN MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 ($
MILLIONS) 90
FIGURE 38 EUROPEAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY
COUNTRY, THROUGH 2020 ($ MILLIONS) 91
FIGURE 39 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE
STAGE, 2014-2020 ($ MILLIONS) 93
FIGURE 40 EUROPEAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR
TARGET, 2014-2020 ($ MILLIONS) 95
FIGURE 41 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND
DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 ($ MILLIONS) 97
FIGURE 42 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY,
THROUGH 2020 ($ MILLIONS) 99
FIGURE 43 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ALZHEIMER'S
THERAPEUTICS, 2014-2020 ($ MILLIONS) 100
FIGURE 44 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM
OF ACTION, 2014-2020 ($ MILLIONS) 102
FIGURE 45 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC
ACETYLCHOLIN-ESTERASE INHIBITORS, 2014-2020 ($ MILLIONS) 103
FIGURE 46 ASIA-PACIFIC MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY
COUNTRY, 2014-2020 ($ MILLIONS) 104
FIGURE 47 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020
($ MILLIONS) 105
FIGURE 48 ASIA-PACIFIC MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 ($
MILLIONS) 106
FIGURE 49 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE
STAGE, 2014-2020 ($ MILLIONS) 107
FIGURE 50 ASIA-PACIFIC MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR
TARGET, 2014-2020 ($ MILLIONS) 109
FIGURE 51 ALZHEIMER'S DRUGS IN THE PIPELINE BY DEVELOPMENT STAGE
(NUMBER OF DRUGS) 112
FIGURE 52 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER
OF DRUGS) 113
FIGURE 53 LATE PHASE II/III ALZHEIMER'S DRUGS BY DISEASE STAGE (NUMBER OF
DRUGS) 114
FIGURE 54 GLOBAL CLINICAL TRIALS ON ALZHEIMER'S DRUG BY MECHANISM OF
ACTION (%) 116
FIGURE 55 FDA-APPROVED CDX TECHNOLOGIES BY INDICATED THERAPEUTIC CLASS
(%) 132
FIGURE 56 FDA-APPROVED CDX-DRUG PAIRS BY MOLECULAR TARGET 132
FIGURE 57 ONGOING AB AND TAU PET IMAGING CLINICAL TRIALS (%) 135
FIGURE 58 AB AND TAU PET IMAGING TRIALS BY CLINICAL TRIAL PHASE (NUMBER
OF TRIALS) 136

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Opioid Market in Iran

  • December 2016
    8 pages
  • Opioid  

  • Iran  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Related Market Segments :

Therapy

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.